The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2021 | CALGB 50801: PET adapted therapy in bulky stage I/II HL
Ann LaCasce, MD, MMSc, Dana-Farber Cancer Institute, Boston, MA, summarizes the findings from the Phase II CALGB 50801 trial (NCT01118026) assessing positron emission tomography (PET)-adapted therapy in bulky stage I/II classic Hodgkin lymphoma. Patients initially received ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) treatment. Patients who subsequently had a PET2- scan received further ABVD treatment without radiotherapy, whereas patients with a PET2+ scan received BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone) with radiotherapy. Patients with PET2- scans had a good outcome with a high progression-free survival rate, avoiding the late toxicities associated with radiotherapy, and patients with PET2+ scans had similar outcomes. This interview took place during the 2021 International Conference on Malignant Lymphoma (16-ICML).
